VACCINES –
THE KEY PARADIGM FOR THE 21st CENTURY'S HEALTH CARE STRATEGY

5th Semmering Vaccine Symposium

 

Program 2011

Scientific Advisory Board:
Rafi Ahmed (Emory University School of Medicine), Thomas Decker (University of Vienna), Noel Barrett (Baxter), Franz X. Heinz (University of Vienna), Hans Wigzell (Karolinska Institute).

Download program (pdf, 1.2MB)

THURSDAY, APRIL 28, 2011

15:00-15:40

WELCOME ADDRESS AND KEY NOTE LECTURE

Welcome address: Alexander von Gabain, MFPL of the University of Vienna, Chair of the SAB of Intercell, Vienna, Austria

Key note speaker: Martin Shuurmans, Chair of the Governing Board, European Institute of Innovation and Technology (EIT)
EIT: Create ecosystems that nurture new business creation for Europe

15:40-16:00

Coffee break

SESSION 1: Badly needed novel vaccines

16:00-16:20

Franz Xaver Heinz, University of Vienna, Institute of Virology, Vienna, Austria
Flaviviruses

16:20-16:40

Ginamarie Foglia, Sanofi Pasteur, Swiftwater, USA
C difficile

16:40-17:00

Peter Lawætt Andersen, Statens Serum Institut, Copenhagen, Denmark
TB Programs

17:00-17:20

Wayne C. Koff, International AIDS Vaccine Initiative, New York, USA
Challenges and opportunities in HIV vaccine development

17:20-18:00

Challenge panel:

Michael Pfleiderer, Paul Ehrlich Institute, Langen, Germany
Andrew Baum, Morgan Stanley & Co. International Limited, London, UK

18:00-19:00

OPENING POSTER SESSION AND GET TOGETHER

Opening Poster Session

19:00-

Dinner

FRIDAY, APRIL 29, 2011

SESSION 2: What vaccinologists expect from immunologists

08:30-08:50

Richard Malley, Harvard Medical School, Children’s Hospital, Boston, USA
Role of TH17 in the pneumococcal immune response

08:50-09:10

Giorgio Trinchieri, National Cancer Institute at Frederick, Frederick, USA
Regulation of adaptive immunity by NK cells

09:10-09:30

Jay A. Berzofsky, National Cancer Institute, Bethesda, USA
TLR ligands, cytokines, and the T cell response

09:30-09:50

Georg Stingl, General Hospital Vienna, Vienna, Austria
Different DCs – different functions

09:50-10:30

Challenge panel:            

Michael Pride, Pfizer Inc., Pearl River, New York, USA
Rino Rappuoli,
Novartis Vaccines, Siena, Italy.
Thomas Decker, Max F. Perutz Laboratories, Vienna, Austria

10:30-11:00

Morning break

SESSION 3: About allergies, autoimmunity, microbes and vaccines

11:00-11:20

Andrew T. Gewirtz, Emory University, School of Medicine, Atlanta, USA
I
nnate immune regulation of gut microbiota and potential therapeutic opportunities to treat metabolic disease and chronic infections

11:20-11:40

Birgit Linhart, Medical University of Vienna, Vienna, Austria
A vaccine for the treatment of grass pollen allergy based on hypoallergenic hybrid molecules

11:40-12:00

Bengt Björkstén, Karolinska institute, Stockholm, Sweden
The
Hygiene Hypothesis; Consequences for vaccine development

12:00-12:20

Peter Zerhouni, Diamyd Medicals, Stockholm, Sweden
A diabetes vaccine

12:20-13:00

Challenge panel:

Hans Wigzell, Karolinska Institute, Stockholm, Sweden
Philippe Moingeon, Stallergenes S.A., Antony Cedex, France

13:00-14:30

Lunch break

SESSION 4: Novel adjuvants – breakthroughs and setbacks,
where will we end?

14:30-14:50

Hermann Wagner, Technical University Munich, München, Germany
Adjuvants and innate immunity

14:50-15:10

Ozzie Berger, GlaxoSmithKline Biologicals, Wavre, Belgium
TLR-4: From research to registered vaccines

15:10-15:30

Derek O´Hagan, Novartis Vaccine and Diagnostics, Cambridge, USA
MF59

15:30-15:50

Veit Hornung, University Hospital Bonn, Bonn, Germany
Role of the inflammasome in adjuvanticity

15:50-16:10

Claire-Ann Siegrist, University of Geneva, Geneva, Switzerland
Neonatal immunization: which challenges for novel vaccines?

16:10-16:50

Challenge panel:

Steven G. Reed, IDRI - Infectious Disease Research Institute, Seattle, USA
Martin Friede
, World Health Organization, Geneva, Switzerland
Sefik S. Alkan, Alkan Consulting LLC, Basel, Switzerland

16:50-18:30

Long afternoon break

18:30-19:15

AUSTRIAN EVENING

In the footsteps of The Third Man
- A cinematic and musical journey through Vienna
Rare and unusual filmic views of Vienna - presented by Michael Loebenstein
Famous Viennese zithermusic live and authentic in style - played by Cornelia Mayer

19:30-

Dinner 
Buffet with traditional Austrian food and live-cooking of “Kaiserschmarren” (Austrian dessert)

SATURDAY, APRIL 30, 2011

SESSION 5: Improving administration also for vaccines in the less developed world

08:30-08:50

Larry Ellingsworth, Intercell USA, Gaithersburg, USA
Patch technology

08:50-09:10

Martine Denis, Sanofi Pasteur, Marcy l’Etoile, France
Microneedle technology and its application to influenza vaccination by the intradermal route

09:10-09:30

Michael Royals, PharmaJet, Golden, Colorado, USA
Enhancing vaccination outcomes with an ID jet injection device

09:30-09:50

George Mutwiri, University of Saskatchewan, Saskatoon, Canada
PCPP-based microneedles

09:50-10:30

Challenge panel:

Maria Elena Bottazzi, The George Washington University, Washington, USA
Andreas Meinke, Intercell AG, Vienna, Austria
Christoph Klade, Intercell AG, Vienna, Austria

10:30-11:00

Morning break

SESSION 6: Quo vadis flu vaccines – learning from the H1N1 pandemic in the light of new technologies and established paradigms

11:00-11:20

Lone Simonsen, The George Washington University, Washington, USA
Signature features and health burden of the 2009 H1N1 pandemic and historic pandemics

11:20-11:40

Klaus Stöhr, Novartis Vaccines and Diagnostics, Cambridge, USA
Novel influenza vaccines: how will they meet health needs

11:40-12:00

Derek Smith, University of Cambridge, UK
The antigenic evolution of influenza virus

12:00-12:20

Gerald Aichinger, Baxter Innovations GmbH, Vienna, Austria
A cell culture flu vaccine

12:20-12:40

Thomas Hofstaetter, VaxInnate, Cranbury, USA
A simple approach to a flu vaccine

12:40-13:20

Challenge panel:     

John Oxford, Queen Mary School of Medicine, London, UK
Michael Perdue,
U.S. Department of Health & Human Services, Washington, USA      

13:20-15:00

Lunch break

SESSION 7: Late breakers in vaccine development

15:00-15:20

Jessica Flechtner, Genocea Biosciences, Cambridge, USA
T cell vaccines

15:20-15:40

Michael Wacker, GlycoVaxyn AG, Schlieren, Switzerland
Paradigm shift in discovery and production of glycoconjugate vaccines

15:40-16:00

Robert Sims, Dendreon Corporation, Seattle, USA
Sipuleucel-T: Autologous cellular immunotherapy for prostate cancer

16:00-16:20

Maria Elena Bottazzi, The George Washington University, Washington, USA
Advances in the development of vaccines against neglected tropical diseases

16:20-16:40

Karl Josef ("Kajo") Kallen, CureVac GmbH, Tübingen, Germany
RNA-based vaccines: a new approach to immunization

16:40-17:00

Afternoon break

CONCLUDING PANEL DISCUSSION:

Need and acceptance of vaccines – how to deal with it?
Panel on the importance of vaccines for global health care and how to deal with fear

17:00-18:00

Stanley Plotkin, Consultant in Vaccinology, Doylestown, USA
Fred Zepp, Johannes Gutenberg University of Mainz, Germany
John Shiver,
Merck & Co., Inc., West Point, USA
Thomas Szucs, European Center of Pharmaceutical Medicine, University of Basel, Switzerland
Shan Lu, University of Massachusetts Medical School, Worcester, USA

Chairman: Alexander von Gabain, MFPL of the University of Vienna, Chair of the SAB of Intercell, Vienna, Austria

19:00- …

CLOSING DINNER